Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa (NCT00346476), a registered phase not stated study. The primary outcome is Number of Participants With Microbiologically Confirmed Tuberculosis Infection.

2. Clinical Question

3. Trial Design

The registry describes a study in Masiphumelele Township, Cape Town, South Africa, focused on tuberculosis and HIV in a community where the study rationale notes high rates of both conditions. Its stated purpose includes determining the number of people infected with tuberculosis, examining the genetics of tuberculosis, and exploring relationships among active tuberculosis infection, new HIV infections, and HIV disease progression. The official title also frames the work around antiretroviral therapy, tuberculosis rates, and transmission.

The record lists 1250 participants. The participant description includes individuals potentially exposed to tuberculosis and/or HIV. The study is marked completed, with a start date of 2006-04 and a primary completion date of 2010-12. The primary outcome is a count of participants with microbiologically confirmed tuberculosis infection at Year 5. The record also lists secondary outcomes concerning tuberculosis clustering and transmission, changes after the introduction of HAART, diversity of tuberculosis strains across participant groups, and recurrent cases attributed to endogenous reactivation versus exogenous reinfection.

This is not presented as a randomized comparison. The registry states that allocation is not stated and that the arms are not a like-for-like control comparison. It lists one participant group rather than separate randomized treatment arms. The study's questions about HAART use and participant subgroups therefore should not be read as evidence of assigned treatment groups or a randomized treatment effect. The registry record does not report further details about recruitment, follow-up procedures, sampling, diagnostic procedures, or a prespecified statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Microbiologically Confirmed Tuberculosis Infection, measured over At Year 5.

The primary endpoint is the number of participants with microbiologically confirmed tuberculosis infection at Year 5. It is a count outcome: the measure is how many participants meet the stated case definition, rather than a difference in an average continuous measurement. Microbiological confirmation indicates that the endpoint depends on evidence from a microbiological assessment, but the registry record does not report the specific test, specimen, case criteria, or confirmation procedure.

A count of confirmed cases can describe the burden identified under a study's measurement procedures. The microbiological component can make case classification more explicit than a symptom-based description alone. However, interpreting a count requires knowing who was assessed, how the case definition was applied, and whether all eligible participants had outcome information. Those details, including the denominator for the Year 5 assessment, are not reported in the registry record.

The endpoint's timeframe is At Year 5. The registry does not report the observed count or a corresponding proportion, estimate of uncertainty, or comparison between groups. Accordingly, the listed endpoint identifies what the study intended to measure, but by itself does not establish the observed tuberculosis burden or the precision of that measurement.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a participant count. In general, a count records how many individuals meet an event definition during a stated assessment period. Here, the event is microbiologically confirmed tuberculosis infection and the timeframe is At Year 5. A count is not automatically a rate or a proportion: a rate requires a time-at-risk denominator, while a proportion requires a defined group of participants who could have met the endpoint. The registry does not report the denominator used for the primary outcome, so neither a rate nor a proportion can be interpreted from the listed endpoint alone.

What does a count tell the reader?

A count can be useful for describing the number of recorded cases, but its meaning depends on how participants entered the assessment and how cases were identified. If some participants did not have an assessment, the observed count may not describe the full enrolled group. If case identification differs across participants, the count may also reflect those measurement procedures. These are general considerations; the registry does not report the Year 5 assessment completeness or the microbiological methods used.

The record calls the outcome microbiologically confirmed. In general, an explicit confirmation criterion can improve clarity about what qualifies as a case. To evaluate reproducibility, readers would need the diagnostic definition and procedures, including what evidence was accepted and how uncertain or incomplete assessments were handled. Those details are not reported in the registry record. Thus the endpoint title communicates the broad kind of evidence required, but not enough to reconstruct the case classification.

How should uncertainty be assessed?

In general, an estimate describes the quantity calculated from study observations, while a confidence interval communicates the statistical uncertainty around that estimate under the analysis assumptions. A narrow interval indicates greater precision than a wide interval, but neither a point estimate nor interval alone addresses bias from selection, measurement, or missing data. The registry does not report the primary count, a confidence interval, or a statistical model. Precision therefore cannot be assessed from the posted results.

A p value, when reported, addresses compatibility between data and a specified statistical hypothesis under assumptions; it does not measure the size or importance of an effect. No p value or hypothesis test is reported for this record. Readers should not infer statistical significance from the existence of a named endpoint or from the study's stated objectives.

What does the design imply for group comparisons?

The registry says this is not a randomized comparison and that allocation is not stated. In general, random allocation can help balance measured and unmeasured characteristics between assigned groups, whereas comparisons among naturally occurring groups may be affected by differences in who belongs to each group. The record mentions distinctions by HIV status and HAART use among secondary outcomes, but does not provide a primary comparison or explain how such differences were analyzed. Any causal interpretation of group contrasts would require design and analysis details not reported in the registry record.

The title and aims refer to the effects of antiretroviral therapy on tuberculosis rates and transmission. That wording describes the question; it does not, on its own, establish that the registry reports an effect estimate. The record gives no treatment assignment procedure, adjustment strategy, or comparative statistical result. No treatment effect should be inferred from the topic or outcome labels.

What can planning calculations establish?

In general, sample-size planning considers the outcome, target effect, variability, significance level, power, and allocation assumptions. The registry describes a planning illustration based on a fraction of an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. It distinguishes illustrations for event-time outcomes from participant-per-arm illustrations for other outcomes. These assumptions describe a planning framework, not the study's own design justification. The registry record does not report the trial's sample-size justification, and no numerical planning result or observed effect estimate is available for interpretation. A planning illustration is not observed power and cannot replace an analysis of the collected data.

For count outcomes, general statistical models may need to address whether variability exceeds what a simple count model assumes; this is called over-dispersion. When over-dispersion is present, a model that assumes less variability than the data contain can produce uncertainty estimates that are too small. Whether over-dispersion was assessed, or whether any count model was used, is not reported in the registry record. No model should be attributed to this study based only on the endpoint type.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Participants")
n      <- c(1250)
events <- c(20)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Participants  1250  20  1.6  1.0  2.5  1.0  2.5  1.0  2.5

11. Multiplicity, Missing Data and Analysis Populations

The registry lists six outcome measures, including a primary tuberculosis count and secondary outcomes on tuberculosis clustering, transmission, strain diversity, and recurrent cases. When a study examines multiple outcomes or comparisons, general statistical practice considers multiplicity: repeated testing can increase the chance that at least one result appears notable by chance. Researchers may address this through a prespecified hierarchy, adjusted testing, or clear emphasis on estimates and uncertainty. The registry record does not report a multiplicity strategy, outcome hierarchy beyond naming the primary outcome, or an analysis plan.

Missing data are also relevant to interpreting a Year 5 count. In general, if outcome status is unavailable for some participants, the count among assessed participants may not represent all enrolled participants. Evaluation requires knowing who was eligible for assessment, how many had outcome data, why information was missing, and what assumptions or methods were used. The record lists enrollment of 1250 but does not report the number assessed for the primary endpoint, missingness, exclusions, or methods for handling unavailable outcomes.

The analysis population is not defined in the registry record. It does not say whether the primary outcome was evaluated among all enrolled participants, a subset meeting eligibility criteria, or participants with available microbiological results. The record also lists zero analyses, so there is no reported statistical population or model to review. These omissions limit reproducibility and make it difficult to assess whether the stated endpoint and the reported safety entries use consistent participant sets.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry's adverse-event entry lists the Participants group with 1250 at risk and 0 affected in the serious-event fields, and 1250 at risk and 0 affected in the other-event fields. It lists no serious-event terms. These entries describe what the registry record reports; they are not a full account of safety monitoring.

In general, an at-risk count identifies the population considered in an event summary, while an affected count records participants reported with an event under that reporting category. To understand such fields, readers would need the event definitions, ascertainment period, collection methods, reporting threshold, and completeness of follow-up. Those details are not reported in the registry record. The entries do not establish that every participant had complete safety surveillance, nor do they explain whether events were attributed to a study treatment or other cause.

The study is not described as a randomized comparison, and the record does not identify treatment assignment. Therefore these safety figures cannot be used to compare treatment groups or estimate a treatment-related risk. The absence of listed serious-event terms should be read as an absence of terms in the registry entry, not as evidence that no serious events occurred during the study.

13. What the Result Does, and Does Not, Mean

The record identifies a community study of tuberculosis and HIV in Masiphumelele Township and names a primary endpoint: the number of participants with microbiologically confirmed tuberculosis infection at Year 5. It also describes broader interests in tuberculosis prevalence, genetics, transmission, HIV disease progression, and HAART. These details establish the subject and intended measurements, not the study's numerical findings.

The result does not, as recorded, state the primary case count, the number assessed, or an uncertainty interval. It therefore cannot establish the observed prevalence or precision of the Year 5 measurement. The fact that enrollment was 1250 does not provide the outcome denominator: the number enrolled and the number with evaluable outcome information need not be identical, and the registry does not report the latter.

The record also does not establish whether HAART changed tuberculosis rates or transmission. It states that allocation is not stated and that the study is not a randomized comparison. Its references to groups based on HIV status and HAART use are outcome descriptions, not evidence of comparable groups or a causal contrast. Without reported group results and analysis methods, the association or effect of treatment cannot be evaluated from this record.

Likewise, zero analyses are listed, and there are no reported effect estimates, confidence intervals, p values, or model outputs. The posted information cannot support conclusions about statistical significance, effect size, or robustness. The serious and other adverse-event fields list 0 affected, but the record's limited event detail does not prove that no events occurred or establish safety in any treatment group.

The appropriate reading is therefore descriptive and cautious: the registry records the study's aims, enrollment, endpoint, and selected reporting fields, while leaving the principal outcome result and its analysis unreported. Conclusions about tuberculosis burden, transmission, treatment effects, or safety would require results and methods not reported in the registry record.

14. Why This Trial Matters Statistically

This study is statistically interesting because it connects several kinds of evidence: a community count of microbiologically confirmed tuberculosis, tuberculosis strain characteristics, transmission patterns, recurrent disease, HIV status, and HAART use. Each question calls for careful definition of the population, outcome, and comparison. The registry's primary endpoint is a participant count at Year 5, while its secondary outcomes address several distinct biological and epidemiological questions.

The record also illustrates why a study's stated aim and its design need to be read together. The official title asks about effects of antiretroviral therapy, but the registry notes that this is not a randomized comparison and that allocation is not stated. This distinction matters because an observed difference between groups defined by treatment use is not automatically a treatment effect. Group composition, outcome ascertainment, and analytic adjustment can affect comparisons, and those details are not reported in the registry record.

Another statistical issue is the difference between identifying an outcome and reporting its result. A named endpoint clarifies what investigators intend to count, but interpretation requires the observed count, denominator, and uncertainty. The registry lists 1250 participants and a Year 5 outcome, yet does not report the primary result or an analysis. Consequently, readers can identify the intended measurement but cannot assess its magnitude or precision.

Finally, the several outcomes raise general questions about outcome prioritization, missingness, and multiplicity. A clear analysis plan helps readers distinguish primary evidence from exploratory findings and assess whether conclusions account for the number of questions examined. Such a plan and its implementation are not reported in the registry record. The statistical importance of the study's subject is therefore clear, while the record's available results are insufficient for evaluating the empirical findings.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting this record is that it does not report the observed primary outcome count. Although the endpoint specifies microbiologically confirmed tuberculosis infection at Year 5 and enrollment is listed as 1250, the number assessed and the denominator for the outcome are not reported in the registry record. Without those details, the outcome cannot be converted into or interpreted as a prevalence estimate, and its precision cannot be evaluated.

The registry does not describe the microbiological case definition, diagnostic procedure, specimen collection, or confirmation rules. These details matter because outcome measurement determines who is counted. The record also does not report follow-up completeness, missing outcome data, exclusions, or the analysis population. It is therefore not possible to judge whether the endpoint reflects all enrolled participants or a subset with available assessments.

The study's stated interest in antiretroviral therapy is not accompanied by a reported randomized allocation or a specified comparator. The record explicitly notes that it is not a randomized comparison and that allocation is not stated. It does not provide group-specific results, adjustment methods, or causal analyses. Treatment-related conclusions cannot be assessed from the listed aims alone.

The registry lists six outcome measures but zero analyses. It does not report a statistical analysis plan, model choices, uncertainty estimates, hypothesis tests, or a multiplicity approach. It also does not report the study's sample-size justification. The planning assumptions described in the record should not be taken as evidence that the study was designed or analyzed according to a particular protocol.

Safety interpretation is similarly limited: the registry lists 0 affected in the serious and other event fields, but does not define ascertainment, event windows, or reporting completeness. These limitations concern what is documented in the registry record and do not establish what methods or results may exist elsewhere.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa — NCT00346476.
• Registry record last updated 2011-02-11; status last verified 2011-02.
• Results first posted 2011-02-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT00346476 is a completed study titled Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa. Its official title concerns antiretroviral therapy, tuberculosis rates, and transmission. The record lists enrollment of 1250, a start date of 2006-04, and a primary completion date of 2010-12.

The primary endpoint is the number of participants with microbiologically confirmed tuberculosis infection at Year 5. Listed secondary outcomes concern tuberculosis clustering and transmission, HAART, tuberculosis strain diversity, and recurrent cases. The registry notes that the study is not a randomized comparison and that allocation is not stated. It lists six outcome measures and zero analyses.

The primary outcome result, denominator, analysis methods, and uncertainty estimates are not reported in the registry record. Adverse-event fields list 0 affected in both serious and other reporting categories, with no serious-event terms listed; the record does not provide further ascertainment details.